Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

INTRODUCTION: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive non–small-cell lung cancer (NSCLC) to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the efficacy of pembrolizumab versus chemotherapy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansfield, Aaron S., Herbst, Roy S., de Castro, Gilberto, Hui, Rina, Peled, Nir, Kim, Dong-Wan, Novello, Silvia, Satouchi, Miyako, Wu, Yi-Long, Garon, Edward B., Reck, Martin, Robinson, Andrew G., Samkari, Ayman, Piperdi, Bilal, Ebiana, Victoria, Lin, Jianxin, Mok, Tony S.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474394/
https://www.ncbi.nlm.nih.gov/pubmed/34590048
http://dx.doi.org/10.1016/j.jtocrr.2021.100205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474394/
https://www.ncbi.nlm.nih.gov/pubmed/34590048
http://dx.doi.org/10.1016/j.jtocrr.2021.100205

Ejemplares similares